Dr Emilio Porfiri qualified in Medicine in 1982 and specialised in Oncology in 1985. He was awarded a PhD from the Royal Free Hospital School of Medicine, London, in 1993.
From 1992 until 1997 he worked at ONYX Pharmaceuticals, Richmond, California, participating in the development of novel cancer therapeutics. From 1997 until 2003 he was a Lecturer and Honorary Consultant in Medical Oncology at the University of Ancona, Italy. Since August 2003 he is Senior Lecturer and Honorary Consultant in Medical Oncology at the University of Birmingham. His main scientific interests are the study of new treatments for renal cancer, in particular tyrosine kinase inhibitors, and the gene therapy of prostate cancer. His research is funded by the Medical Research Council, Department of Health, Queen Elizabeth Hospital Birmingham Charity, Pfizer, GlaxoSmithKline.
Click here for further information